Ken Griffin Morpho Sys Ag Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$17.36 - $19.34 $1.19 Million - $1.33 Million	-68,800 Reduced 79.08%	18,200 $331,000
Q1 2024 May 15, 2024	SELL	$8.6 - $18.18 $1.23 Million - $2.6 Million	-143,100 Reduced 62.19%	87,000 $1.58 Million
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $953,680 - $2.08 Million	209,600 Added 1022.44%	230,100 $2.28 Million
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $120,288 - $153,940	17,900 Added 688.46%	20,500 $137,000
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $10,270 - $20,124	2,600 New	2,600 $19,000

1.84M

79.8K

688K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.